LOGIN
The efficacy & safety of various doses of fulranumab vs placebo for chronic LBP
January 2017
The efficacy & safety of various doses of fulranumab vs placebo for chronic LBP
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study
Clin Ther. 2016 Jun;38(6):1435-50Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
389 patients with moderate-to-severe chronic low back pain (LBP) were randomized to receive one of five dose-ranging subcutaneous injection treatments: 1mg fulranumab every 4 weeks, 3mg fulranumab every 4 weeks, 3mg fulranumab every 4 weeks after a 6mg loading dose, 10mg fulranumab every 4 weeks, or placebo every 4 weeks. The purpose of this study was to determine the efficacy and safety of fulran...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.